I don't think I'm saying that Kemery.
The app and clinical / radiologic diagnosis were never going to agree 100%. There was always going to be clinical review of cases where there was disagreement.
If you were to learn that there was only 10 cases out of 1200 requiring clinical review this tells you there is very good agreement. If there was 500 very poor agreement.
Even if you have met the agreement standards on the first pass you would still undertake the clinical review as this would be part and parcel of the protocol. And forms part of the FDA submission.
If the time difference is relatively small (as a week is) you would not normally release the results in two parts.
If the time difference was large – it was going to take 6 months to perform this clinical review then yes you would provide what you might describe as “interim” results now with “final” results down the track.
- Forums
- ASX - By Stock
- RAP
- Ann: Voluntary Suspension
Ann: Voluntary Suspension, page-68
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 404 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online